Reading An I Pad

The Medtech[y] Minute

Posted on November 02, 2016 by Medtech[y] Staff

It's been a busy week on the boards and our new blog, The Ticker, so we thought it would be helpful to round up the most popular topics and articles from the week and make it easy on you.

Feel free to share your thoughts on the boards or just read and enjoy. If you like the site, please take a minute to like our Facebook page, LinkedIn Company Page or tell your colleagues about us.

Thanks for helping us grow!


This week on the boards

Intersect ENT's stock falls over 40% Wednesday - Is this a sign that the business is in trouble or just a reaction from a JP Morgan downgrade? Do you work at Intersect and have an opinion? If so, share your thoughts.

Medtronic Message Board - Discussions include: SynchroMedII received a Urgent Field Safety Notice , Medtronic is under a hiring freeze and travel restriction and a great question about products being transferred out of the Gunbarrel site. Join in.

Zimmer Biomet Message Board - Zimmer Biomet is a relatively new board on the site and there is a great discussion about the recent earnings report and a Biomet potentially not shipping product.

Depuy Synthes Message Board - The Depuy loosening thread continues to be highly visited. Are you a physician or rep who has insight into these potential issues? Share if you do. 

Bioventus Message Board - Relatively new board, Bioventus, gets going as a recent studies shows their Exogen therapy may not work as advertised.

Popular Ticker Articles 

Former Walgreens Clinical Pharmacy Manager Pleads Guilty To $4.4 Million TennCare Fraud Scheme - Hepatitis C prescription costs were already under intense scrutiny due to their high costs, and stories like this will do nothing but keep them in the news. In a recent blog post, we reviewed the GoodRx list of the most expensive drugs of 2016 and four of the top 10 on the list were Hepatitis C drugs. 

4 Tips for Managing a New Medical Sales Territory - A number of sales reps think sales success happens because you can schmooze and are a likable person. There is no doubt those factors can lead to one-off successes, but long-term success in sales is due to strategy and planning.

Stryker still going after ex-rep, despite bankruptcy - Ex-Stryker rep, Chris Ridgeway, has been in the middle of a legal battle with Stryker since September 2013 when they fired and sued him, claiming he conspired with Biomet to steal Stryker's trade secrets, pricing, and obtain a distributorship deal through Ridgeway's side business, Stone Surgical, LLC. 

The 10 Most Expensive Prescriptions of 2016 - Healthcare startup, GoodRx, recently published their list of the most expensive prescriptions in the U.S. The data is gathered by using actual prices from a sample of claims reported by pharmacies throughout the United States.